Epidemiology of TB, National University San Antonio Abad de Cusco, Lima, Peru
Eur Respir Rev. 2021 Mar 24;30(159). doi: 10.1183/16000617.0107-2020. Print 2021 Mar 31.
The production of tuberculosis (TB) research and innovation in Latin America during the past decade has notably improved. Its role in the acceleration of the decline of the average annual TB incidence rate by 2.5% from 2017 to 2018 is still unclear, but it is looking promising that the region will meet the End TB Strategy targets set for 2030. Well performed and high-quality research and evidence is critical for improving national TB control programme outcomes. In Latin America, this need is most apparent when responding to the multidrug-resistant TB epidemic.There is an urgent need for technological breakthroughs to accelerate by an average of 17% per year if the decline in TB incidence rate is to meet the target set for 2030. Intensified research and innovation, identified as one of the three essential pillars of the End TB Strategy, has scarcely been achieved in the region due to political and economic context. This will be analysed further in this article.
过去十年，拉丁美洲在结核病（TB）研究和创新方面的产出显著提高。但尚不清楚它在加速 2017 年至 2018 年期间结核病发病率平均每年下降 2.5%方面的作用，不过该地区有望实现 2030 年终止结核病战略目标。高质量的研究和证据对于改善国家结核病控制规划的成果至关重要。在拉丁美洲，应对耐多药结核病疫情时，这一需求最为明显。如果要实现 2030 年设定的结核病发病率下降目标，就需要平均每年取得 17%的技术突破，这是一个紧迫的需求。加强研究和创新，被确定为终止结核病战略的三个基本支柱之一，但由于政治和经济背景，该地区几乎没有实现这一目标。本文将进一步对此进行分析。
